MuhammadFurqanMD

Clinical Trials

• Pharmacological Ascorbate for Lung Cancer Start of enrollment: 2015 Apr 01

  Completed

  Phase 2

• Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer Start of enrollment: 2016 Aug 29

  Active, not recruiting

  Phase 2

• Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01

  Completed

  Phase 2

• Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01

  Completed

  Phase 2, Phase 3

• Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29

  Active, not recruiting

  Phase 3

• PDR001 + Panobinostat for Melanoma and NSCLC Start of enrollment: 2019 Sep 01

  Withdrawn

  Phase 1

• Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2021 Apr 20

  Recruiting

  Phase 2

  Roles: Principal Investigator, Contact, Sponsor-Investigator

• Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer Start of enrollment: 2021 Aug 21

  Recruiting

  Roles: Contact

• A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC Start of enrollment: 2018 Nov 16

  Recruiting

  Phase 2

  Roles: Contact, Principal Investigator

• Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2023 Oct 23

  Recruiting

  Phase 1

  Roles: Sponsor-Investigator, Contact, Principal Investigator

• Join now to see all